Iwilfin Disease Interactions
There are 3 disease interactions with Iwilfin (eflornithine).
Eflornithine (applies to Iwilfin) hearing loss
Moderate Potential Hazard, Moderate plausibility.
Eflornithine can cause hearing loss. New or worsening hearing loss requiring new use of hearing aids occurred in 7% of patients in clinical trials. An audiogram should be performed prior to initiation of therapy and at 6 month intervals, or as clinically indicated, to monitor new or worsening hearing loss.
Eflornithine (applies to Iwilfin) liver dysfunction
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease
The pharmacokinetics of eflornithine have not been studied in patients with moderate or severe liver dysfunction.
Eflornithine (applies to Iwilfin) renal impairment
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction
Patients with moderate (eGFR <60 mL/min) and severe (eGFR <30 mL/min) renal impairment have a higher exposure to eflornithine than patients with normal renal function which can increase the risk of adverse effects and toxicity. Reduce the dose by 50% in patients with severe renal impairment. Monitor patients closely for increased adverse reactions including hepatotoxicity, myelosuppression, and hearing loss.
Switch to professional interaction data
Iwilfin drug interactions
There are 208 drug interactions with Iwilfin (eflornithine).
Report options
More about Iwilfin (eflornithine)
- Iwilfin consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous antineoplastics
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
